Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance

Published: Aug 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

FLEMINGTON, N.J., Aug. 21, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has initiated a pharmacokinetic (PK) study of onapristone. The initiation follows the submission and approval of an Investigational Medicinal Product Dossier (IMPD) by the French Health Authority, L'Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM).

Help employers find you! Check out all the jobs and post your resume.

Back to news